Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Ataxin-2 repeat-length variation and neurodegeneration.

Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, DeJesus-Hernandez M, Adamson J, Li M, Volkening K, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Woodruff BK, Knopman DS, White CL 3rd, Van Gerpen JA, Meschia JF, Mackenzie IR, Boylan K, Boeve BF, Miller BL, Strong MJ, Uitti RJ, Younkin SG, Graff-Radford NR, Petersen RC, Wszolek ZK, Dickson DW, Rademakers R.

Hum Mol Genet. 2011 Aug 15;20(16):3207-12. doi: 10.1093/hmg/ddr227. Epub 2011 May 24.

PMID:
21610160
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.

Bonini NM, Gitler AD.

J Mol Neurosci. 2011 Nov;45(3):676-83. doi: 10.1007/s12031-011-9548-9. Epub 2011 Jun 10. Review.

PMID:
21660502
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?

van den Heuvel DM, Harschnitz O, van den Berg LH, Pasterkamp RJ.

Trends Mol Med. 2014 Jan;20(1):25-35. doi: 10.1016/j.molmed.2013.09.001. Epub 2013 Oct 16. Review.

PMID:
24140266
[PubMed - indexed for MEDLINE]
4.

Progress in pathogenesis studies of spinocerebellar ataxia type 1.

Cummings CJ, Orr HT, Zoghbi HY.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1079-81. Review.

PMID:
10434309
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Spinocerebellar ataxia type 1.

Zoghbi HY.

Clin Neurosci. 1995;3(1):5-11. Review.

PMID:
7614095
[PubMed - indexed for MEDLINE]
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk